FR2843303B1 - Nouvelles compositions pharmaceutiques destinees au traitement de l'incontinence urinaire - Google Patents

Nouvelles compositions pharmaceutiques destinees au traitement de l'incontinence urinaire

Info

Publication number
FR2843303B1
FR2843303B1 FR0210058A FR0210058A FR2843303B1 FR 2843303 B1 FR2843303 B1 FR 2843303B1 FR 0210058 A FR0210058 A FR 0210058A FR 0210058 A FR0210058 A FR 0210058A FR 2843303 B1 FR2843303 B1 FR 2843303B1
Authority
FR
France
Prior art keywords
treatment
pharmaceutical compositions
urinary incontinence
novel pharmaceutical
musculotropic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0210058A
Other languages
English (en)
Other versions
FR2843303A1 (fr
Inventor
Caroline Rougaignon
Michel Lanquetin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
R&D PHARMA
R & D Pharma
Original Assignee
R&D PHARMA
R & D Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R&D PHARMA, R & D Pharma filed Critical R&D PHARMA
Priority to FR0210058A priority Critical patent/FR2843303B1/fr
Priority to AU2003283153A priority patent/AU2003283153A1/en
Priority to PCT/FR2003/002471 priority patent/WO2004014360A2/fr
Priority to US10/524,131 priority patent/US20060100182A1/en
Priority to EP03756527A priority patent/EP1526855A2/fr
Publication of FR2843303A1 publication Critical patent/FR2843303A1/fr
Application granted granted Critical
Publication of FR2843303B1 publication Critical patent/FR2843303B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Abstract

L'invention se rapporte au domaine de la chimie thérapeutique et en particulier au domaine de la pharmacotechnie.Elle concerne de nouvelles compositions pharmaceutiques destinées au traitement de l'incontinence urinaire, notamment chez la femme par une association d'une substance cholinergique et musculotrope d'une part, et d'un agent estrogène peu résorbé par voie locale caractérisée en ce que la substance cholinergique et musculotrope est l'oxybutynine ou un de ses sels et que l'agent estrogène peu résorbé est choisi parmi l'estriol, le 16-epiestriol ou l'estradiol sous forme libre, estérifiée et/ou éthérifiée. L'invention se caractérise en outre par le fait que l'administration s'effectue sous une des formes appropriées par la voie vaginale.Utilisation de cette composition pharmaceutique par voie vaginale.
FR0210058A 2002-08-07 2002-08-07 Nouvelles compositions pharmaceutiques destinees au traitement de l'incontinence urinaire Expired - Lifetime FR2843303B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR0210058A FR2843303B1 (fr) 2002-08-07 2002-08-07 Nouvelles compositions pharmaceutiques destinees au traitement de l'incontinence urinaire
AU2003283153A AU2003283153A1 (en) 2002-08-07 2003-08-06 Pharmaceutical compositions for the treatment of urinary incontinence
PCT/FR2003/002471 WO2004014360A2 (fr) 2002-08-07 2003-08-06 Compositions pharmaceutiques destinees au traitement de l'incontinence urinaire
US10/524,131 US20060100182A1 (en) 2002-08-07 2003-08-06 Pharmaceutical compositions for the treatment of urinary incontinence
EP03756527A EP1526855A2 (fr) 2002-08-07 2003-08-06 Compositions pharmaceutiques destinees au traitement de l'incontinence urinaire

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0210058A FR2843303B1 (fr) 2002-08-07 2002-08-07 Nouvelles compositions pharmaceutiques destinees au traitement de l'incontinence urinaire

Publications (2)

Publication Number Publication Date
FR2843303A1 FR2843303A1 (fr) 2004-02-13
FR2843303B1 true FR2843303B1 (fr) 2006-01-21

Family

ID=30470993

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0210058A Expired - Lifetime FR2843303B1 (fr) 2002-08-07 2002-08-07 Nouvelles compositions pharmaceutiques destinees au traitement de l'incontinence urinaire

Country Status (5)

Country Link
US (1) US20060100182A1 (fr)
EP (1) EP1526855A2 (fr)
AU (1) AU2003283153A1 (fr)
FR (1) FR2843303B1 (fr)
WO (1) WO2004014360A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
GB201601855D0 (en) * 2016-02-02 2016-03-16 Inura Medical Ag Urethral devices for treatment of pathological urological conditions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
KR20010029519A (ko) * 1996-09-19 2001-04-06 이곤 이 버그 요실금 치료 방법
US6436428B1 (en) * 2000-03-21 2002-08-20 Enhance Pharmaceuticals, Inc. Device and method for treating urinary incontinence in females
EP1438035A2 (fr) * 2001-09-27 2004-07-21 Pharmacia AB Compositions pharmaceutiques pour le traitement de troubles urinaires
WO2004043429A1 (fr) * 2002-11-12 2004-05-27 Pharmacia & Upjohn Company Therapie combinee pour traiter les dysfonctionnements d'ordre sexuel chez la femme apres la menopause, comprenant un agent androgene, un oestrogene et une agent antimuscarinique
US20060058777A1 (en) * 2002-12-11 2006-03-16 Pia Norup Nielsen Urinary catheter device with a pharmaceutically active composition
WO2004073679A1 (fr) * 2003-02-13 2004-09-02 Mulholland S Grant Suppositoire uretral renforce
CN1791399A (zh) * 2003-03-21 2006-06-21 戴诺根医药品公司 用α2δ亚基钙通道调节剂和平滑肌调节剂一起治疗下泌尿道病症的方法

Also Published As

Publication number Publication date
AU2003283153A8 (en) 2004-02-25
US20060100182A1 (en) 2006-05-11
WO2004014360A2 (fr) 2004-02-19
WO2004014360A3 (fr) 2004-04-08
FR2843303A1 (fr) 2004-02-13
EP1526855A2 (fr) 2005-05-04
AU2003283153A1 (en) 2004-02-25

Similar Documents

Publication Publication Date Title
MX2009005307A (es) Nuevas composiciones bajo la forma de ungüento libre de vaselina, que comprenden un derivado de vitamina d y eventualmente un anti-inflamatorio esteroide.
BR0200155A (pt) Tratamento combinado para depressão
TNSN98211A1 (fr) Association d'un inhibiteur d'aldose-reductase et d'un inhibiteur de glycogene-phosphorylase, et composition pharmaceutique la contenant
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
BR0317747A (pt) Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave
TNSN98125A1 (fr) Sels de sertraline, et formes posologiques de sertraline a liberation prolongee, et procedes pour leur preparation
TNSN01125A1 (fr) Compositions pharmaceutiques comprenant un inhibiteur de cetp et de l'atorvastatine
EA200201000A1 (ru) Гормон-заместительная терапия
BR0108930A (pt) Método de fornecimento de um agente ativo a um tipo celular de interesse, composição farmacêutica, pró-droga ativada por caspase, kit, método de tratamento de mamìferos, uso de um conjugado de caspase e uso de um pró-agente
DE10190041D2 (de) Implantate, Partikel
TNSN04112A1 (fr) Formes de sels de e-2-methoxy-n-(3-4-(3-methyl-pyridine-3-yloxy)-phenylamino)-quinazoline-6-yl)-allyl)-acetamide, leur preparation et leur utilisation contre le cancer
NZ513810A (en) Compositions and methods for improved delivery of hydrophobic therapeutic agents
EP2260845A3 (fr) Utilisation de polyphénol pour le traitement de l'alopécie
HUP0004339A2 (hu) Nõk kezelési eljárása menopauzát követõen ultra-alacsony dózisú ösztrogénnel
TR200100812T2 (tr) Akut ağrı tedavisi için fentanil kompozisyon.
BR0009167A (pt) Inibidores de enzima impdh
WO2006044916A3 (fr) Utilisation d'inhibiteurs de la na+/k+-atpase et leurs antagonistes
BR0015346A (pt) Formulação farmacêutica contendo tolterodina e seu uso
EP1658849A3 (fr) combinaisons therapeutiques contenant des agents antihypotensives et antiangiogeniques
HUP0004350A2 (hu) Vegyületek női szexuális diszfunkció kezelésére
DE60138468D1 (de) Cyanophenoxy-carbonsäuren und zusammensetzungen für die freisetzung aktiver substanzen
BR0005765A (pt) Combinação de inibidores de aldose redutase e agentes anti-hipertensivos para o tratamento de complicações diabéticas
TNSN01170A1 (fr) Associations d'agonistes de gaba et d'inhibiteurs d'aldose-reductase.
AR011231A1 (es) Uso de un mejorador de sensibilidad a la insulina y composicion farmaceutica que comprende dicho mejorador
BRPI0607999A2 (pt) método para o alìvio de sintomas, o tratamento ou a prevenção do cáncer, uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais hidróxi cromanos selecionados do grupo que consiste em 7:8-dimetil 6-hidróxi cromanos (delta), 8-metil 6-hidróxi cromanos (gama), e as misturas dos mesmos, conjuntamente com um veìculo ou um diluente apropriado, método para a indução da apoptose celular, método para aumentar a eficácia de um agente anticáncer, método para aumentar a eficácia do licopeno, formulação farmacêutica

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16